A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects
Sign Up to like & getrecommendations! Published in 2019 at "Psychopharmacology"
DOI: 10.1007/s00213-019-05366-1
Abstract: Rationale Phosphodiesterase 10A inhibitor TAK-063 has shown effects that suggest efficacy in schizophrenia treatment. Objective This randomized, double-blind, placebo-controlled, incomplete-crossover study investigated effects of single oral administration of TAK-063 on ketamine-induced changes in blood oxygen… read more here.
Keywords: fmri bold; ketamine induced; bold signal; placebo ... See more keywords